BRAF and colorectal carcinoma: However, few genetic markers have demonstrated prognostic or predictive value for the treatment decision in MSI CRC, such as the V600E mutation of B-type raf proto-oncogene (BRAF) [12] and the HSP110 T17 deletion [13], leaving room to find new candidates.